Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INGE-B palbociclib combination study in HR-positive/HER2-negative advanced breast cancer
2015-001603-32Phase 2Completed
- Sponsor
- iOMEDICO
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of palbociclib in breast cancer (2 arms), sponsored by iOMEDICO. Primary endpoint: Primary efficacy endpoint. Started Feb 2016; status: completed.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2015-001603-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001603-32.